PharmaEngine, Inc.(TW:4162)
NT$52.50-0.30 (-0.57%)
TW:4162
PharmaEngine, Inc. financials statements
NT$52.50
At close:-0.30 (-0.57%)
PharmaEngine, Inc. (4162) Ratios
PharmaEngine, Inc. Ratios
TW:4162's free cash flow for Q2 2026 was NT$98.57M. For the 2026 fiscal year, TW:4162's free cash flow was decreased by NT$-224.00K and operating cash flow was NT$98.79M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 27.17 | 13.15 | 46.78 | 49.86 | 45.71 |
| Quick Ratio | 26.96 | 13.09 | 46.59 | 49.43 | 45.65 |
| Cash Ratio | 8.46 | 2.24 | 10.44 | 22.47 | 24.52 |
| Solvency Ratio | 1.79 | 3.93 | 3.12 | 3.47 | 4.97 |
| Operating Cash Flow Ratio | 9.23 | 1.03 | 3.06 | 2.57 | 10.60 |
| Short-Term Operating Cash Flow Coverage | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Current Asset Value | NT$ 4.86B | NT$ 5.38B | NT$ 3.83B | NT$ 3.83B | NT$ 3.92B |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.01 | 0.00 | 0.00 | 0.01 | 0.00 |
| Debt-to-Equity Ratio | 0.01 | 0.00 | 0.00 | 0.01 | 0.00 |
| Debt-to-Capital Ratio | 0.01 | 0.00 | 0.00 | 0.01 | 0.00 |
| Long-Term Debt-to-Capital Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Financial Leverage Ratio | 1.04 | 1.08 | 1.02 | 1.02 | 1.02 |
| Debt Service Coverage Ratio | 2862.10 | 9726.62 | 916.07 | 4252.87 | 2058.99 |
| Interest Coverage Ratio | 3060.87 | 11343.46 | 894.14 | 3672.03 | 1709.78 |
| Debt to Market Cap | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Debt Per Share | 0.29 | 0.05 | 0.11 | 0.16 | 0.05 |
| Net Debt to EBITDA | -2.97 | -0.45 | -2.48 | -4.35 | -3.86 |
| Profitability Margins | |||||
| Gross Profit Margin | 93.21% | 98.11% | 93.66% | 92.41% | 94.34% |
| EBIT Margin | 55.89% | 85.73% | 44.07% | 59.99% | 83.32% |
| EBITDA Margin | 57.00% | 86.10% | 45.24% | 61.30% | 84.89% |
| Operating Profit Margin | 46.68% | 81.37% | 36.11% | 43.21% | 55.35% |
| Pretax Profit Margin | 55.88% | 85.72% | 44.03% | 59.97% | 83.29% |
| Net Profit Margin | 42.53% | 69.39% | 35.78% | 48.72% | 65.06% |
| Continuous Operations Profit Margin | 42.53% | 69.39% | 35.78% | 48.72% | 65.06% |
| Net Income Per EBT | 76.11% | 80.95% | 81.26% | 81.23% | 78.11% |
| EBT Per EBIT | 119.70% | 105.35% | 121.93% | 138.80% | 150.46% |
| Return on Assets (ROA) | 7.53% | 29.94% | 6.95% | 8.04% | 10.58% |
| Return on Equity (ROE) | 7.87% | 32.43% | 7.11% | 8.23% | 10.82% |
| Return on Capital Employed (ROCE) | 8.58% | 37.99% | 7.16% | 7.27% | 9.20% |
| Return on Invested Capital (ROIC) | 6.52% | 30.71% | 5.81% | 5.90% | 7.18% |
| Return on Tangible Assets | 7.53% | 29.95% | 6.95% | 8.04% | 10.58% |
| Earnings Yield | 3.83% | 13.50% | 1.74% | 1.78% | 4.06% |
| Efficiency Ratios | |||||
| Receivables Turnover | 2.88 | 1.36 | 2.83 | 2.92 | 4.08 |
| Payables Turnover | 1.74 | 0.00 | 0.00 | 0.00 | 0.00 |
| Inventory Turnover | 1.55 | 1.68 | 3.06 | 1.45 | 6.82 |
| Fixed Asset Turnover | 20.40 | 246.37 | 42.58 | 25.25 | 82.96 |
| Asset Turnover | 0.18 | 0.43 | 0.19 | 0.16 | 0.16 |
| Working Capital Turnover Ratio | 0.18 | 0.55 | 0.20 | 0.17 | 0.17 |
| Cash Conversion Cycle | 152.15 | 486.16 | 248.31 | 377.31 | 142.93 |
| Days of Sales Outstanding | 126.83 | 269.21 | 129.13 | 124.86 | 89.45 |
| Days of Inventory Outstanding | 235.08 | 216.95 | 119.18 | 252.46 | 53.48 |
| Days of Payables Outstanding | 209.76 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Cycle | 361.91 | 486.16 | 248.31 | 377.31 | 142.93 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | 12.02 | 3.18 | 1.79 | 1.41 | 6.43 |
| Free Cash Flow Per Share | 12.02 | 3.17 | 1.78 | 1.38 | 6.43 |
| Dividend Paid and CapEx Coverage Ratio | 2.00 | 2.11 | 0.89 | 0.52 | 2.55 |
| Capital Expenditure Coverage Ratio | 6167.32 | 322.78 | 623.71 | 51.22 | 4059.69 |
| Operating Cash Flow Coverage Ratio | 40.99 | 63.94 | 17.35 | 9.04 | 122.44 |
| Operating Cash Flow to Sales Ratio | 1.89 | 0.18 | 0.33 | 0.31 | 1.42 |
| Free Cash Flow Yield | 17.07% | 3.51% | 1.62% | 1.10% | 8.86% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | 26.07 | 7.43 | 57.59 | 56.31 | 24.61 |
| Price-to-Sales (P/S) Ratio | 11.10 | 5.14 | 20.60 | 27.43 | 16.02 |
| Price-to-Book (P/B) Ratio | 2.05 | 2.40 | 4.09 | 4.64 | 2.66 |
| Price-to-Free Cash Flow (P/FCF) Ratio | 5.86 | 28.49 | 61.63 | 90.62 | 11.29 |
| Price-to-Operating Cash Flow Ratio | 5.86 | 28.40 | 61.53 | 88.85 | 11.29 |
| Price-to-Earnings Growth (PEG) Ratio | -0.34 | 0.01 | -4.12 | -2.28 | -0.85 |
| Enterprise Value Multiple | 16.50 | 5.52 | 43.05 | 40.39 | 15.02 |
| Enterprise Value | 8.57B | 11.98B | 14.95B | 16.20B | 8.35B |
| EV to EBITDA | 16.50 | 5.52 | 43.05 | 40.39 | 15.02 |
| EV to Sales | 9.41 | 4.75 | 19.48 | 24.76 | 12.75 |
| EV to Free Cash Flow | 4.97 | 26.32 | 58.27 | 81.80 | 8.98 |
| EV to Operating Cash Flow | 4.96 | 26.24 | 58.18 | 80.21 | 8.98 |
| Tangible Book Value Per Share | 34.28 | 37.58 | 26.86 | 26.95 | 27.25 |
| Shareholders’ Equity Per Share | 34.29 | 37.59 | 26.87 | 26.97 | 27.25 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.24 | 0.19 | 0.19 | 0.19 | 0.22 |
| Revenue Per Share | 6.34 | 17.57 | 5.34 | 4.56 | 4.53 |
| Net Income Per Share | 2.70 | 12.19 | 1.91 | 2.22 | 2.95 |
| Tax Burden | 0.76 | 0.81 | 0.81 | 0.81 | 0.78 |
| Interest Burden | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
| Research & Development to Revenue | 0.33 | 0.11 | 0.40 | 0.28 | 0.21 |
| SG&A to Revenue | 0.14 | 0.06 | 0.17 | 0.21 | 0.18 |
| Stock-Based Compensation to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Income Quality | 4.45 | 0.21 | 0.94 | 0.51 | 1.70 |
Currency in TWD
